• Comenzo, R.L. & Gertz, M.A. (2002) Autologous stem cell transplantation for primary systemic amyloidosis. Blood, 99, 42764282.
  • Gertz, M.A., Kyle, R.A. & Greipp, P.R. (1991) Response rates and survival in primary systemic amyloidosis. Blood, 77, 257262.
  • Kyle, R.A. & Greipp, P.R. (1983) Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clinic Proceedings, 58, 665683.
  • Moreau, P., Leblond, V., Bourquelot, P., Facon, T., Huynh, A., Caillot, D., Hermine, O., Attal, M., Hamidou, M., Nedellec, G., Ferrant, A., Audhuy, R., Bataille, R., Milpied, N. & Harousseau, J.L. (1998) Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. British Journal of Haematology, 101, 766769.
  • Sanchorawala, V., Wright, D.G., Seldin, D.C., Falk, R.H., Berk, J., Dember, L.M., Finn, K.T. & Skinner, M. (2002) Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. British Journal of Haematology, 117, 886889.
  • Seldin, C.D., Choufani, E., Skinner, M., Wright, D.G., Dember, J., Weisman, J., Fennessey, K., Finn, K. & Sanchorawala, V. (2001) A phase I/II trial of thalidomide for patients with AL amyloidosis. Blood, 11, 164a.